{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:11:57Z","timestamp":1787991117328,"version":"build-2784847793"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijid.2025.108081","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T01:59:32Z","timestamp":1759629572000},"page":"108081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort"],"prefix":"10.1016","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9896-489X","authenticated-orcid":false,"given":"Mariacristina","family":"Poliseno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Lo","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tavelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Antonia","family":"Santantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adndrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"d\u2019Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cozzi-Lepri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108081_bib0001","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1060028016660812","article-title":"Tenofovir alafenamide: a review of its use in the treatment of HIV-1 infection","volume":"50","author":"Gibson","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijid.2025.108081_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijid.2019.07.011","article-title":"Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: a meta-analysis of randomized controlled trials","volume":"87","author":"Tao","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108081_bib0003","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/hiv.13106","article-title":"Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofoviral afenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study","volume":"22","author":"Kovari","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2025.108081_bib0004","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxilfumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijid.2025.108081_bib0005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/QAI.0000000000003079","article-title":"Brief report: effect of antiretroviral switch from tenofovir disoproxil fumarate to tenofovir alafenamide on alanine aminotransferase, lipid profiles, and renal function in HIV\/HBV-co-infected individuals in a nationwide Canadian study","volume":"91","author":"Sarowar","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2025.108081_bib0006","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.2147\/DDDT.S274307","article-title":"The effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on liver enzymes, glucose, and lipid profile","volume":"14","author":"Squillace","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ijid.2025.108081_bib0007","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/hiv.12984","article-title":"Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?","volume":"22","author":"Gazzola","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2025.108081_bib0008","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijid.2025.108081_bib0009","first-page":"526","article-title":"Tenofovir alafenamide (TAF) clinical pharmacology","volume":"29","author":"Di Perri","year":"2021","journal-title":"Infez Med"},{"key":"10.1016\/j.ijid.2025.108081_bib0010","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2025.108081_bib0011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAI.0000000000002429","article-title":"Brief report: switching from TDF to TAF in HIV\/HBV-coinfected individuals with renal dysfunction-A prospective cohort study","volume":"85","author":"Surial","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2025.108081_bib0012","article-title":"Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients","volume":"11","author":"Zhao","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.ijid.2025.108081_bib0013","unstructured":"The ICONA Foundation Study Cohort, www.fondazioneICONA.org \u2013; n.d. [accessed 24 August 2025]."},{"key":"10.1016\/j.ijid.2025.108081_bib0014","unstructured":"NCEP ATP III. (USA): National Cholesterol Education Program, https:\/\/www.nhlbi.nih.gov\/health-topics\/high-blood-cholesterol; 2024 [accessed 24 August 2025]."},{"key":"10.1016\/j.ijid.2025.108081_bib0015","unstructured":"EUROPEAN SOCIETY OF CARDIOLOGY, EAS. European Guidelines on Cardiovascular Disease Prevention Program, https:\/\/www.escardio.org; 2025 [accessed 24 August 2025]."},{"key":"10.1016\/j.ijid.2025.108081_bib0016","unstructured":"KDIGO. Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines, https:\/\/kdigo.org; n.d. [accessed 24 August 2025]."},{"key":"10.1016\/j.ijid.2025.108081_bib0017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5487\/TR.2018.34.3.221","article-title":"Investigating organ toxicity profile of tenofovir and tenofovir nanoparticle on the liver and kidney: experimental animal study","volume":"34","author":"Peter","year":"2018","journal-title":"Toxicol Res"},{"key":"10.1016\/j.ijid.2025.108081_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2023.12.011","article-title":"Endothelial dysfunction, a predictor of cardiovascular disease in HIV patients on antiretroviral therapy: a systematic review and meta-analysis","volume":"234","author":"Strauss","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.ijid.2025.108081_bib0019","doi-asserted-by":"crossref","first-page":"ofab621","DOI":"10.1093\/ofid\/ofab621","article-title":"Lipid changes after switch from TDF to TAF in the OPERA cohort: LDL-cholesterol and triglycerides","volume":"9","author":"Mallon","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.108081_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261760","article-title":"Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B","volume":"17","author":"Suzuki","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108081_bib0021","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/hiv.70037","article-title":"Safety and effectiveness of switch to bictegravir\/emtricitabine\/tenofoviralafenamide following dual regimen therapy in people with HIV: insights from the ICONA cohort","volume":"26","author":"De Vito","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2025.108081_bib0022","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108081_bib0023","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciae374","article-title":"Effect of 2 forms of tenofovir on duodenal enterocytes-A hypothesis for different effects of tenofovir disoproxil fumarate and tenofovir alafenamide on body weight and plasma lipids","volume":"80","author":"Kauppinen","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108081_bib0024","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00535-020-01750-3","article-title":"Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection","volume":"56","author":"Suzuki","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ijid.2025.108081_bib0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QAD.0000000000003455","article-title":"Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in vitro model","volume":"37","author":"Perna","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108081_bib0026","series-title":"San Francisco: Top Antiviral Medicine Conference: CROI \u2013 Conference on Retroviruses and Opportunistic Infections Abstract","article-title":"Body composition changes in people with HIV switching from or maintaining TDF-based regimens","volume":"893","author":"Milic","year":"2025"},{"key":"10.1016\/j.ijid.2025.108081_bib0027","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108081_bib0028","unstructured":"BRITISH H.I.V. ASSOCIATION. A rapid guidance on the use of statins, https:\/\/bhiva.org\/wp-content\/uploads\/2024\/10\/BHIVA-rapid-guidance-on-the-use-of-statins.pdf; 2024 [accessed 24 August 2025]."},{"key":"10.1016\/j.ijid.2025.108081_bib0029","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-5876-9-13","article-title":"Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications","volume":"9","author":"L\u00f3pez-Novoa","year":"2011","journal-title":"J Transl Med"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225003030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:07:10Z","timestamp":1780664830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225003030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"alternative-id":["S1201971225003030"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108081","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term trajectories of hepatic and metabolic biomarkers after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral therapy-experienced people with HIV with and without hepatic coinfection: Data from the ICONA cohort","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108081"}}